Thrombocyte Activity Reassessment and GEnoTyping for PCI(TARGET-PCI)

This study has been terminated.
(Lack of financial support)
Sponsor:
Information provided by (Responsible Party):
Kevin Bliden, LifeBridge Health
ClinicalTrials.gov Identifier:
NCT01177592
First received: August 6, 2010
Last updated: March 18, 2014
Last verified: March 2014
  Purpose

This is a prospective, single-center, randomized trial including 1500 subjects requiring PCI. Subjects with ischemic heart disease due to stenotic lesions in either native coronary arteries or coronary artery bypass undergoing PCI with stent placement and no contraindication to prolonged dual antiplatelet therapy (≥1 year) are eligible to be in the study. Subjects will be randomized to either guided antiplatelet therapy arm (n=750) or standard therapy arm (n=750) and undergo laboratory testing, antiplatelet adjustment, and clinical follow-up for 1 year.

Patients (non-emergent) presenting for PCI will receive standard pre-procedural PCI care as outlined by the current ACC/AHA guidelines. Subjects will be consented peri- PCI (prior to or within 24 hours of PCI) and then randomized (1:1 ratio) to guide or standard non-guided (control) antiplatelet therapy. Physicians will be blinded to genotyping and platelet function results for subjects randomized to the standard therapy group for the duration of the study or if endpoint is met. Subjects on chronic clopidogrel or prasugrel therapy (≥ 2 weeks) will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing (see flow schematic). Patients randomized to the control arm will remain on 75mg clopidogrel arm throughout the study. All patients will remain on 325mg ASA for one month and 81-162 mg daily ASA thereafter.

Clinical follow-up (office visit) and post-PCI VerifyNow maintenance testing will occur at 2 weeks, 3 months, and 6 months for patients in the guided therapy group. VerifyNow testing, adverse event occurrence and drug compliance will be performed as part of follow-up. Patients having a measurement of ≥ 230 PRU at 2 weeks or the 3 month visit will be reloaded with 60 mg prasugrel and receive standard maintenance dosing thereafter until the 6-month visit. Patients in guided and control study arms will return at 6 months for clinical follow-up and VerifyNow testing. After completing 6 months of the study treatment period, further antiplatelet therapy will be at the physician's discretion. At 1 year, study subjects will be contacted via phone for clinical assessment and antiplatelet compliance. Physicians adjudicating events will be blinded to the therapy assignment.


Condition Intervention
Coronary Artery Disease
Device: VerifyNow, Verigene

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Thrombocyte Activity Reassessment and GEnoTyping for PCI(TARGET-PCI)

Resource links provided by NLM:


Further study details as provided by LifeBridge Health:

Primary Outcome Measures:
  • MACE [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    To demonstrate a 30% relative risk reduction in post-PCI ischemic event occurrence (composite of cardiovascular death, ischemic stroke, non-fatal myocardial infarction, urgent target vessel revascularization) with personalized guided antiplatelet treatment as compared to standard post-intervention treatment


Secondary Outcome Measures:
  • Major, Minor, and Nuisance Bleeding [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    To demonstrate no significant differences in major, minor, and nuisance bleeding with guided therapy as compared to conventional therapy.

  • MACE [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    To compare CYP2C19 guided therapy with VerifyNow P2Y12 guided approach in relation to MACE.

  • Predicting MACE [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    To determine if a combined (genetic and platelet) approach for guiding therapy is superior to a single approach (genetic or platelet) for predicting MACE.

  • Overcoming HPR [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    To demonstrate efficacy of prasugrel in overcoming high platelet reactivity as compared to clopidogrel maintenance therapy.

  • Platelet Reactivity, Verify Now [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To determine the stability of platelet reactivity over time as measured by VerifyNow.

  • VerifyNow and Bleeding [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To determine a relation between VerifyNow P2Y12 results and bleeding events (medically relevant major, minor, and nuisance).

  • Verify Now and Ischemic Event [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To determine a relation between VerifyNow P2Y12 results and ischemic event occurrence.

  • CYP2C19, ischemia and bleeding [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To determine the relation of CYP2C19 variants to ischemia and bleeding.

  • HPR in prasugrel treatment [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To determine the incidence of HPR (as define by PRU ≥230) in prasugrel treated subjects.

  • Genotype guided therapy [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To demonstrate feasibility of genotype guided therapy with the Verigene System by evaluation of test turnaround time, ease of use and reliability in a point of care setting.

  • Algorithm [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To develop an optimal or "recommended" algorithm for guided antiplatelet therapy integrating genotyping and platelet function testing.

  • Utilizing Patient Questionnaire [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To assess the utility of the personalized antiplatelet approach in clinical practice (utilizing a physician questionnaire)

  • Cutpoints for Plateletworks [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To determine cutpoints for ischemic and bleeding risk using the Plateletworks Assay.

  • Platelet Mapping [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To determine a relation between platelet mapping results and bleeding.

  • Platelet Mapping and Ischemic Event [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To determine a relation between platelet mapping results and ischemic event occurrence.


Enrollment: 7
Study Start Date: July 2010
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Guided Therapy
Subjects on chronic clopidogrel therapy (≥ 5 days maintenance or loading within 4 hours of PCI) will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing
Device: VerifyNow, Verigene
Subjects on chronic clopidogrel will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing (see flow schematic).
No Intervention: Standard Therapy
Patients randomized to the control arm will remain on 75mg clopidogrel arm throughout the study.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must be between ages 18-85.
  • Patients undergoing PCI.
  • Patients undergoing coronary angiography and possible PCI with planned use of at least one drug-eluting stent (DES). One or more bare metal stents (BMS) may be implanted, and other lesions may be treated without stenting, as long as at least one DES is implanted. However the procedure must be successful and uncomplicated for all lesions (DES + BMS + non stent).
  • Indication for the procedure may be stable angina or ischemia, unstable angina, non-ST elevation MI (NSTEMI).
  • Have the ability to understand the requirements of the study, including consent for use and disclosure of research-related health information.
  • Have the ability to comply with study procedures and protocol, including required study visits.
  • A female patient is eligible to enter the study if she is (1) of child-bearing potential and not pregnant or nursing; (2) not of child bearing potential (i.e. has had a hysterectomy, have both ovaries removed, has tubal ligation, or if she is post-menopausal, defined as 24 months without menses).

Exclusion Criteria:

  • Cardiovascular

    • Cardiogenic shock.
    • Ischemic Stroke within 6 weeks
    • Planned staged PCI in the next 6 months post-procedure
    • Unsuccessful PCI (post-procedure diameter stenosis >30% with less than TIMI-3 flow in any treated vessel).
    • Patients with in-hospital STEMI confirmed by ECG prior to randomization or those whom require a target vessel revascularization of the index lesion prior to randomization.
    • Major complication during or after PCI such as but not limited to need for balloon pump, acute stent thrombosis, and major bleed.
  • Prior or concomitant therapy

    • Concurrent or planned treatment with warfarin.
    • IIb/IIIa Inhibitors within 72 hrs of PCI
    • Current or planned treatment with Cilostazol
    • Current treatment with Prasugrel
  • Hemorrhagic risk

    • History of bleeding diathesis or evidence of active abnormal bleeding within 30 days of randomization.
    • History of hemorrhagic stroke or sub-arachnoid hemorrhage at any time or stroke or TIA of any etiology within 30 days of randomization.
    • Major surgery within 6 weeks prior to randomization.
    • Known platelet count of <100,000/mm3.
    • PT > 1.5 x control.
    • HCT < 25% or > 52%.
    • History of gastro-intestinal bleeding within 6 months.
    • Considered by investigator to be at high-risk for bleeding on long-terms clopidogrel therapy.
    • Minor surgical procedures that require cessation of dual antiplatelet therapy and result in significant bleeding are NOT eligible.
  • General

    • Known allergy or contraindication to heparin, aspirin, clopidogrel, or prasugrel.
    • Participation in a study of experimental therapy or device within prior 30 days.
    • Creatinine level of greater than 4.0 mg/dl.
    • Known history of alcohol or drug abuse.
    • Pregnant women or women of child-bearing potential not using an acceptable method of contraception.
    • Severe allergy to stainless steel, contrast dye, unfractionated heparin, low molecular weight heparin, or bivalirudin that cannot be adequately pre-medicated.
    • Current enrollment in an investigational drug or device study that has not reached the time period of the primary endpoint.
    • Patients unwilling or unable to complete clinical follow-up for the duration of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01177592

Locations
United States, Maryland
Sinai Center for Thrombosis Research
Baltimore, Maryland, United States, 21215
Sponsors and Collaborators
LifeBridge Health
Investigators
Principal Investigator: Paul A Gurbel, M.D. Sinai Hospital of Baltimore
  More Information

No publications provided

Responsible Party: Kevin Bliden, Sinai Center for Thrombosis Research Program Manager, LifeBridge Health
ClinicalTrials.gov Identifier: NCT01177592     History of Changes
Other Study ID Numbers: 1714
Study First Received: August 6, 2010
Last Updated: March 18, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Clopidogrel
Platelet Aggregation Inhibitors
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 20, 2014